RVPH
Reviva Pharmaceuticals Holdings Inc.

4,976
Mkt Cap
$37.51M
Volume
5.01M
52W High
$2.15
52W Low
$0.25
PE Ratio
-0.66
RVPH Fundamentals
Price
$0.3019
Prev Close
$0.326
Open
$0.3275
50D MA
$0.4682
Beta
0.62
Avg. Volume
8.29M
EPS (Annual)
-$0.9026
P/B
6.39
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Investors Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH)
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders acquired 25,745 call options on the...
MarketBeat·1mo ago
News Placeholder
More News
News Placeholder
Why Did RVPH Stock Crash 50% Today?
The company announced that the FDA called for an additional Phase 3 trial of its schizophrenia treatment drug.
Stocktwits·1mo ago
News Placeholder
Reviva Pharmaceuticals (NASDAQ:RVPH) Earns "Buy" Rating from D. Boral Capital
D. Boral Capital reaffirmed a "buy" rating and issued a $2.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday...
MarketBeat·1mo ago
News Placeholder
Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH)
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock traders acquired 27,891 call options on the...
MarketBeat·2mo ago
News Placeholder
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of "Moderate Buy" by Brokerages
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine brokerages that are currently covering the company, MarketBeat.com...
MarketBeat·2mo ago
News Placeholder
Brokers Offer Predictions for RVPH FY2025 Earnings
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - Analysts at Chardan Capital issued their FY2025 earnings per share estimates for Reviva Pharmaceuticals in a research note issued...
MarketBeat·2mo ago
News Placeholder
Does Cobenfy Have the Potential to Become a Top Drug for BMY?
Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline expansion potential.
Zacks·5mo ago
News Placeholder
10 Stocks Retailers Are Most Bullish/Bearish About On Tuesday
Earnings largely impacted sentiment toward stocks that made it to the most bullish and bearish lists on Stocktwits Tuesday.
Stocktwits·1y ago
<
...
1
>

Latest RVPH News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.